A/Prof. Olivia Dean

Efficacy of adjunctive Garcinia mangostana Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial

Melanie Ashton, Michael Berk, Chee Ng, Malcolm Hopwood, Seetal Dodd, Alyna Turner, Ellie Brown, Felice Jacka, Susan Cotton, Jon-Paul Khoo, Mary Chatterton, Bianca Kavanagh, Sarah Nadjidai, Samantha Lo Monaco, Brian Harvey, Jerome Sarris, Gin Malhi, Nathan Dowling, Olivia Dean

(2019), Vol. 41, pp. 245-253, Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

The efficacy of adjunctive N-acetylcysteine in acute bipolar depression: a randomized placebo-controlled study

Pernille Ellegaard, Rasmus Licht, Ren� Nielsen, Olivia Dean, Michael Berk, Henrik Poulsen, Mohammadreza Mohebbi, Connie Nielsen

(2019), Vol. 245, pp. 1043-1051, Journal of affective disorders, Amsterdam, The Netherlands, C1

A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo

Michael Berk, Alyna Turner, Gin Malhi, Chee Ng, Susan Cotton, Seetal Dodd, Yuval Samuni, Michelle Tanious, Claire McAulay, Nathan Dowling, Jerome Sarris, Lauren Owen, Astrid Waterdrinker, Deidre Smith, Olivia Dean

(2019), Vol. 17, pp. 1-11, BMC medicine, London, Eng., C1

The therapeutic potential of mangosteen pericarp as an adjunctive therapy for bipolar disorder and schizophrenia

Melanie Ashton, Olivia Dean, Adam Walker, Chiara Bortolasci, Chee Ng, Malcolm Hopwood, Brian Harvey, Marisa M�ller, John McGrath, Wolfgang Marx, Alyna Turner, Seetal Dodd, James Scott, Jon-Paul Khoo, Ken Walder, Jerome Sarris, Michael Berk

(2019), Vol. 10, pp. 1-17, Frontiers in psychiatry, Lausanne, Switzerland, C1

Protocol and rationale: a 24-week double-blind, randomized, placebo controlled trial of the efficacy of adjunctive garcinia mangostanaLinn. (mangosteen) pericarp for schizophrenia

Alyna Turner, John McGrath, Olivia Dean, Seetal Dodd, Andrea Baker, Susan Cotton, James Scott, Bianca Kavanagh, Melanie Ashton, Adam Walker, Ellie Brown, Michael Berk

(2019), Vol. 17, pp. 297-307, Clinical psychopharmacology and neuroscience, Seoul, South Korea, C1

Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review

Melanie Ashton, Michael Berk, Chee Ng, Malcolm Hopwood, Bianca Kavanagh, Lana Williams, Jerome Sarris, Olivia Dean

(2019), Vol. 9, BMJ Open, London, Eng., C1

Protocol update and statistical analysis plan for CADENCE-BZ: a randomized clinical trial to assess the efficacy of sodium benzoate as an adjunctive treatment in early psychosis

Carmen Lim, Andrea Baker, Sukanta Saha, Sharon Foley, Anne Gordon, David Ward, Bjorn Burgher, Frances Dark, Martin Beckmann, Stephen Stathis, George Bruxner, Alex Ryan, Drew Richardson, Sean Hatherill, Michael Berk, Olivia Dean, John McGrath, Cadence Working Group, James Scott

(2019), Vol. 20, Trials, London, Eng., C1

The effect of blueberry interventions on cognitive performance and mood: a systematic review of randomized controlled trials

Nikolaj Travica, Nathan D'Cunha, Nenad Naumovski, Katherine Kent, Duane Mellor, Joseph Firth, Ekavi Georgousopoulou, Olivia Dean, Amy Loughman, Felice Jacka, Wolfgang Marx

(2019), Brain, behavior and immunity, Amsterdam, The Netherlands, C1

Role of personality disorder in randomised controlled trials of pharmacological interventions for adults with mood disorders: a protocol for a systematic review and meta-analysis

Bianca Kavanagh, Sharon Brennan-Olsen, Alyna Turner, Olivia Dean, Michael Berk, Melanie Ashton, Heli Koivumaa-Honkanen, Lana Williams

(2019), Vol. 9, BMJ open, London, Eng., C1

Personality disorder and functioning in major depressive disorder: a nested study within a randomized controlled trial

Bianca Kavanagh, Lana Williams, Michael Berk, Alyna Turner, Henry Jackson, Mohammadreza Mohebbi, Buranee Kanchanatawan, Melanie Ashton, Chee Ng, Michael Maes, Lesley Berk, Gin Malhi, Nathan Dowling, Ajeet Singh, Olivia Dean

(2019), Brazilian journal of psychiatry, Sao Paulo, Brazil, C1

Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis

Wolfgang Marx, Melissa Lane, Tetyana Rocks, Anu Ruusunen, Amy Loughman, Adrian Lopresti, Skye Marshall, Michael Berk, Felice Jacka, Olivia Dean

(2019), Vol. 77, pp. 557-571, Nutrition reviews, Oxford, Eng., C1

A study protocol for the N-ICE trial: a randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence

Rebecca McKetin, Olivia Dean, Alyna Turner, Peter Kelly, Brendan Quinn, Dan Lubman, Paul Dietze, Gregory Carter, Peter Higgs, Amanda Baker, Barbara Sinclair, David Reid, Victoria Manning, Nina Te Pas, Wenbin Liang, Tamsin Thomas, Ramez Bathish, Margaret Kent, Dayle Raftery, Shalini Arunogiri, Frank Cordaro, Harry Hill, Michael Berk

(2019), Vol. 20, pp. 1-11, Trials, London, Eng., C1

Measuring cognitive insight in people with problematic substance use: an exploration of the factor validity of the Beck Cognitive Insight Scale

D Raftery, P Kelly, F Deane, R Mcketin, A Baker, A Turner, O Dean

(2019), Vol. 38, pp. 622-629, Drug and alcohol review, Chichester, Eng., C1

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial

C Davey, A Chanen, S Hetrick, S Cotton, A Ratheesh, G Amminger, J Koutsogiannis, M Phelan, E Mullen, B Harrison, S Rice, A Parker, O Dean, A Weller, M Kerr, A Quinn, L Catania, N Kazantzis, P McGorry, M Berk

(2019), Vol. 6, pp. 735-744, The Lancet Psychiatry, Amsterdam, The Netherlands, C1

Modulation of high fat diet-induced microbiome changes, but not behaviour, by minocycline

K Hasebe, L Rivera, C Smith, T Allnutt, T Crowley, T Nelson, O Dean, S McGee, K Walder, L Gray

(2019), Vol. 82, pp. 309-318, Brain, behavior, and immunity, Amsterdam, The Netherlands, C1

N-acetylcysteine for cessation of tobacco smoking: rationale and study protocol for a randomised controlled trial

L Arancini, C Bortolasci, S Dodd, O Dean, M Berk

(2019), Vol. 20, pp. 1-7, Trials, London, Eng., C1

Drugs used in the treatment of bipolar disorder and their effects on cholesterol biosynthesis - A possible therapeutic mechanism

S Kidnapillai, C Bortolasci, B Panizzutti, B Spolding, T Connor, K Bonifacio, A Sanigorski, O Dean, T Crowley, S Jamain, L Gray, M Leboyer, M Berk, K Walder

(2019), pp. 1-12, World Journal of Biological Psychiatry, London, Eng., C1

Youth depression alleviation-augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin

A Quinn, O Dean, C Davey, M Kerr, S Harrigan, S Cotton, A Chanen, S Dodd, A Ratheesh, G Amminger, M Phelan, A Williams, A Mackinnon, F Giorlando, S Baird, S Rice, M O'Shea, M Sch�fer, E Mullen, S Hetrick, P McGorry, M Berk

(2018), Vol. 12, pp. 45-54, Early intervention in psychiatry, London, Eng., C1

Garcinia mangostana Linn displays antidepressant-like and pro-cognitive effects in a genetic animal model of depression: a bio-behavioral study in the Flinders Sensitive Line rat

I Oberholzer, M M�ller, B Holland, O Dean, M Berk, B Harvey

(2018), Vol. 33, pp. 467-480, Metabolic brain disease, New York, N.Y., C1

Post-operative cognitive dysfunction: an exploration of the inflammatory hypothesis and novel therapies

D Skvarc, M Berk, L Byrne, O Dean, S Dodd, M Lewis, A Marriott, E Moore, G Morris, R Page, L Gray

(2018), Vol. 84, pp. 116-133, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

An update on adjunctive treatment options for bipolar disorder

O Dean, E Gliddon, T Van Rheenen, F Giorlando, S Davidson, M Kaur, T Ngo, L Williams

(2018), Vol. 20, pp. 87-96, Bipolar disorders, Chichester, Eng., C1

Mechanisms underpinning the polypharmacy effects of medications in psychiatry

Chiara Bortolasci, Briana Spolding, Edward Callaly, Sheree Martin, Bruna Panizzutti, Srisaiyini Kidnapillai, Timothy Connor, Kyoko Hasebe, Mohammadreza Mohebbi, Olivia Dean, Sean McGee, Seetal Dodd, Laura Gray, Michael Berk, Ken Walder

(2018), Vol. 21, pp. 582-591, The international journal of neuropsychopharmacology, Oxford, Eng., C1

Mitochondrial agents for bipolar disorder

C�ria Pereira, Victor Chavarria, Jo�o Vian, Melanie Ashton, Michael Berk, Wolfgang Marx, Olivia Dean

(2018), Vol. 21, pp. 550-569, International journal of neuropsychopharmacology, London, Eng., C1

Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol)

P Ellegaard, R Licht, H Poulsen, R Nielsen, M Berk, O Dean, M Mohebbi, C Nielsen

(2018), Vol. 6, pp. 1-9, International journal of bipolar disorders, Berlin, Germany, C1

Does N-acetylcysteine improve behaviour in children with autism?: A mixed-methods analysis of the effects of N-acetylcysteine

O Dean, K Gray, Seetal Dodd, K Villagonzalo, E Browne, B Tonge, M Berk, L Byrne

(2018), pp. 1-7, Journal of intellectual and developmental disability, London, Eng., C1

Improvement of cognitive function in schizophrenia with N-acetylcysteine: a theoretical review

C Yolland, A Phillipou, D Castle, E Neill, M Hughes, C Galletly, Z Smith, P Francis, O Dean, J Sarris, D Siskind, A Harris, S Rossell

(2018), pp. 1-10, Nutritional neuroscience, Abingdon, Eng., C1

Patient centric measures for a patient centric era: agreement and convergent between ratings on The Patient Global Impression of Improvement (PGI-I) scale and the Clinical Global Impressions - Improvement (CGI-S) scale in bipolar and major depressive disorder

M Mohebbi, S Dodd, O Dean, M Berk

(2018), Vol. 53, pp. 17-22, European psychiatry, Amsterdam, The Netherlands, C1

The use of a gene expression signature and connectivity map to repurpose drugs for bipolar disorder

Srisaiyini Kidnapillai, Chiara Bortolasci, Madhara Udawela, Bruna Panizzutti, Briana Spolding, Timothy Connor, Andrew Sanigorski, Olivia Dean, Tamsyn Crowley, St�phane Jamain, Laura Gray, Elizabeth Scarr, Marion Leboyer, Brian Dean, Michael Berk, Ken Walder

(2018), pp. 1-9, World journal of biological psychiatry, London, Eng., C1

Mediator effects of parameters of inflammation and neurogenesis from a N-acetyl cysteine clinical-trial for bipolar depression

Bruna Panizzutti, Chiara Bortolasci, Kyoko Hasebe, Srisaiyini Kidnapillai, Laura Gray, Ken Walder, Michael Berk, Mohammadreza Mohebbi, Seetal Dodd, Clarissa Gama, Pedro Magalh�es, Susan Cotton, Fl�vio Kapczinski, Ashley Bush, Gin Malhi, Olivia Dean

(2018), Vol. 30, pp. 334-341, Acta neuropsychiatrica, Cambridge, Eng., C1

A potential role for N-acetylcysteine in the management of methamphetamine dependence

R McKetin, O Dean, A Baker, G Carter, A Turner, P Kelly, M Berk

(2017), Vol. 36, pp. 153-159, Drug and alcohol review, London, Eng., C1

A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder

O Dean, K Gray, K-A Villagonzalo, S Dodd, M Mohebbi, T Vick, B Tonge, M Berk

(2017), Vol. 51, pp. 241-249, Australian and New Zealand journal of psychiatry, London, Eng., C1

Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology

J Data-Franco, A Singh, D Popovic, M Ashton, M Berk, E Vieta, M Figueira, O Dean

(2017), Vol. 72, pp. 73-86, Progress in neuro-psychopharmacology & biological psychiatry, Amsterdam, The Netherlands, C1

Cognitive effects of adjunctive N-acetyl cysteine in psychosis

M Rapado-Castro, S Dodd, A Bush, G Malhi, D Skvarc, Z On, M Berk, O Dean

(2017), Vol. 47, pp. 866-876, Psychological medicine, Cambridge, Eng., C1

A model of the mitochondrial basis of bipolar disorder

G Morris, K Walder, S McGee, O Dean, S Tye, M Maes, M Berk

(2017), Vol. 74, pp. 1-20, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial)

F Jacka, A O'Neil, R Opie, C Itsiopoulos, S Cotton, M Mohebbi, D Castle, S Dash, C Mihalopoulos, M Chatterton, L Brazionis, O Dean, A Hodge, M Berk

(2017), Vol. 15, pp. 1-13, BMC medicine, London, Eng., C1

A review of the theoretical and biological understanding of the nocebo and placebo phenomena

S Dodd, O Dean, J Vian, M Berk

(2017), Vol. 39, pp. 469-476, Clinical therapeutics, Amsterdam, The Netherlands, C1

Adjunctive N-acetylcysteine in depression: exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor

K Hasebe, L Gray, C Bortolasci, B Panizzutti, M Mohebbi, S Kidnapillai, B Spolding, K Walder, M Berk, G Malhi, S Dodd, O Dean

(2017), Vol. 29, pp. 337-346, Acta neuropsychiatrica, Cambridge, Eng., C1

The efficacy of sodium benzoate as an adjunctive treatment in early psychosis - Cadence-BZ: study protocol for a randomized controlled trial

A Ryan, A Baker, F Dark, S Foley, A Gordon, S Hatherill, S Stathis, S Saha, G Bruxner, M Beckman, D Richardson, M Berk, O Dean, J McGrath, Cadence Working Group, J Scott

(2017), Vol. 18, pp. 1-11, Trials, London, Eng., C1

the effect of n-acetylcysteine (nac) on human cognition - a systematic review

D Skvarc, O Dean, L Byrne, L Gray, S Lane, M Lewis, B Fernandes, M Berk, A Marriott

(2017), Vol. 78, pp. 44-56, Neuroscience & Biobehavioral Reviews, Amsterdam, The Netherlands, C1

Adjunctive minocycline treatment for major depressive disorder: a proof of concept trial

O Dean, B Kanchanatawan, M Ashton, M Mohebbi, C Ng, M Maes, L Berk, A Sughondhabirom, S Tangwongchai, A Singh, H McKenzie, D Smith, G Malhi, N Dowling, M Berk

(2017), Vol. 51, pp. 829-840, Australian & New Zealand journal of psychiatry, London, Eng., C1

Mitochondrial modifying nutrients in treating chronic fatigue syndrome: a 16-week open-label pilot study

R Menon, L Cribb, J Murphy, M Ashton, G Oliver, N Dowling, A Turner, O Dean, M Berk, C Ng, J Sarris

(2017), Vol. 4, pp. 109-114, Advances in integrative medicine, Amsterdam, The Netherlands, C1

C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications

B Fernandes, J Steiner, H Bernstein, S Dodd, J Pasco, O Dean, P Nardin, C Gon�alves, M Berk

(2016), Vol. 21, pp. 554-564, Molecular psychiatry, London, Eng., C1

A review of vulnerability and risks for schizophrenia: beyond the two hit hypothesis

J Davis, H Eyre, F Jacka, S Dodd, O Dean, S McEwen, M Debnath, J McGrath, M Maes, P Amminger, P McGorry, C Pantelis, M Berk

(2016), Vol. 65, pp. 185-194, Neuroscience & biobehavioral reviews, Amsterdam, The Netherlands, C1

Antioxidant treatments for schizophrenia

P Magalh�es, O Dean, A Andreazza, M Berk, F Kapczinski

(2016), Vol. 2016, pp. 1-93, Cochrane database of systematic reviews, London, Eng., C1

N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis

B Fernandes, O Dean, S Dodd, G Malhi, M Berk

(2016), Vol. 77, pp. 457-466, Journal of clinical psychiatry, Memphis, Tenn., C1

The Post-Anaesthesia N-acetylcysteine Cognitive Evaluation (PANACEA) trial: study protocol for a randomised controlled trial

D Skvarc, O Dean, L Byrne, L Gray, K Ives, S Lane, M Lewis, C Osborne, R Page, D Stupart, A Turner, M Berk, A Marriott

(2016), Vol. 17, pp. 1-11, Trials, London, Eng., C1

N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms

S Rossell, P Francis, C Galletly, A Harris, D Siskind, M Berk, K Bozaoglu, F Dark, O Dean, D Liu, D Meyer, E Neill, A Phillipou, J Sarris, D Castle

(2016), Vol. 16, pp. 1-9, BMC psychiatry, London, Eng., C1

Participant characteristics as modifiers of response to N-Acetyl cysteine (NAC) in obsessive-compulsive disorder

J Sarris, G Oliver, D Camfield, O Dean

(2016), Vol. 4, pp. 1104-1111, Clinical psychological science, London, Eng., C1

Towards stage specific treatments: Effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia.

M Rapado-Castro, M Berk, K Venugopal, A Bush, S Dodd, O Dean

(2015), Vol. 57, pp. 69-75, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Amsterdam, The Netherlands, C1

Oxidative stress and post-stroke depression: possible therapeutic role of polyphenols?

S Nabavi, O Dean, A Turner, A Sureda, M Daglia, S Nabavi

(2015), Vol. 22, pp. 343-351, Current medicinal chemistry, Beijing, China, C1-1

Tobacco use in bipolar disorder.

D Thomson, M Berk, S Dodd, M Rapado-Castro, S Quirk, P Ellegaard, L Berk, O Dean

(2015), Vol. 13, pp. 1-11, Clinical Psychopharmacology and Neuroscience, Korea (South), C1

N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review

G Oliver, O Dean, D Camfield, S Blair-West, C Ng, M Berk, J Sarris

(2015), Vol. 13, pp. 12-24, Clinical psychopharmacology and neuroscience, Korea (South), C1

Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.

Deepmala, J Slattery, N Kumar, L Delhey, M Berk, O Dean, C Spielholz, R Frye

(2015), Vol. 55, pp. 294-321, Neuroscience and Biobehavioral Reviews, Amsterdam, The Netherlands, C1

N-Acetyl Cysteine (NAC) in the treatment of obsessive-compulsive disorder: a 16-week, double-blind, randomised, placebo-controlled study

J Sarris, G Oliver, D Camfield, O Dean, N Dowling, D Smith, J Murphy, R Menon, M Berk, S Blair-West, C Ng

(2015), Vol. 29, pp. 801-809, CNS Drugs, Berlin, Germany, C1

Future directions for pharmacotherapies for treatment-resistant bipolar disorder

S Dodd, B Simoes Fernandes, O Dean

(2015), Vol. 13, pp. 656-662, Current neuropharmacology, Bussum, The Netherlands, C1

Role of immune-inflammatory and oxidative and nitrosative stress pathways in the etiology of depression: Therapeutic implications

G Anderson, M Berk, O Dean, S Moylan, M Maes

(2014), Vol. 28, pp. 1-10, CNS Drugs, C1

Post-stroke depression therapy: Where are we now?

S Nabavi, A Turner, O Dean, A Sureda, S Nabavi

(2014), Vol. 11, pp. 279-289, Current Neurovascular Research, C1

The efficacy of adjunctive N-Acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial

M Berk, O Dean, S Cotton, S Jeavons, M Tanious, K Kohlmann, K Hewitt, K Moss, C Allwang, I Schapkaitz, J Robbins, H Cobb, F Ng, S Dodd, A Bush, G Malhi

(2014), Vol. 75, pp. 628-636, Journal of clinical psychiatry, Memphis, Tenn., C1

Oxidative & nitrosative stress in depression: why so much stress?

S Moylan, M Berk, O Dean, Y Samuni, L Williams, A O'Neil, A Hayley, J Pasco, G Anderson, F Jacka, M Maes

(2014), Vol. 45, pp. 46-62, Neuroscience and biobehavioral reviews, Amsterdam, The Netherlands, C1

Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression

O Dean, A Turner, G Malhi, C Ng, S Cotton, S Dodd, J Sarris, Y Samuni, M Tanious, N Dowling, A Waterdrinker, D Smith, M Berk

(2014), Vol. 0, pp. 1-10, Revista Brasileira de psiquiatria, Sao Paulo, Brazil, C1

The Glutathione System: a new drug target in neuroimmune disorders

G Morris, G Morris, G Anderson, G Anderson, O Dean, O Dean, M Berk, M Berk, P Galecki, P Galecki, M Martin-Subero, M Martin-Subero, M Maes, M Maes

(2014), Vol. 50, pp. 1059-1084, Molecular neurobiology, New York, N. Y., C1

The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.

C Davey, A Chanen, S Cotton, S Hetrick, M Kerr, M Berk, O Dean, K Yuen, M Phelan, A Ratheesh, M Sch�fer, G Amminger, A Parker, D Piskulic, S Harrigan, A Mackinnon, B Harrison, P McGorry

(2014), Vol. 15, pp. 1-9, Trials, London, Eng., C1

Protocol and Rationale-The Efficacy of Minocycline as an Adjunctive Treatment for Major Depressive Disorder: A Double Blind, Randomised, Placebo Controlled Trial.

O Dean, M Maes, M Ashton, L Berk, B Kanchanatawan, A Sughondhabirom, S Tangwongchai, C Ng, N Dowling, G Malhi, M Berk

(2014), Vol. 12, pp. 180-188, Clinical psychopharmacology and neuroscience, Seoul, Korea, C1

Putative neuroprotective agents in neuropsychiatric disorders

S Dodd, M Maes, G Anderson, O Dean, S Moylan, M Berk

(2013), Vol. 42, pp. 135-145, Progress in Neuro-Psychopharmacology and Biological Psychiatry, C1

The promise of N-acetylcysteine in neuropsychiatry

M Berk, G Malhi, L Gray, O Dean

(2013), Vol. 34, pp. 167-177, Trends in Pharmacological Sciences, C1

Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo

P Das, M Tanious, K Fritz, S Dodd, O Dean, M Berk, G Malhi

(2013), Vol. 47, pp. 347-354, Australian and New Zealand Journal of Psychiatry, C1

A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania

P Da Silva Magalh�es, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2013), Vol. 47, pp. 564-568, Australian and New Zealand Journal of Psychiatry, C1

Aspirin: A review of its neurobiological properties and therapeutic potential for mental illness

M Berk, M Berk, O Dean, O Dean, H Drexhage, H Drexhage, J McNeil, J McNeil, S Moylan, S Moylan, A O'Neil, A O'Neil, C Davey, C Davey, L Sanna, L Sanna, M Maes, M Maes

(2013), Vol. 11, pp. 1-17, BMC Medicine, C1

A randomised, controlled trial of a dietary intervention for adults with major depression (the "SMILES" trial): Study protocol

A O'Neil, M Berk, C Itsiopoulos, D Castle, R Opie, J Pizzinga, L Brazionis, A Hodge, C Mihalopoulos, M Chatterton, O Dean, F Jacka

(2013), Vol. 13, BMC Psychiatry, C1

The chemistry and biological activities of N-acetylcysteine

Y Samuni, S Goldstein, O Dean, M Berk

(2013), Vol. 1830, pp. 4117-4129, Biochimica et Biophysica Acta - General Subjects, C1

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder

P Magalh�es, O Dean, A Bush, D Copolov, D Weisinger, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2012), Vol. 37, pp. 132-135, Progress in Neuro-Psychopharmacology and Biological Psychiatry, C1

Minocycline: Therapeutic potential in psychiatry

O Dean, J Data-Franco, F Giorlando, M Berk

(2012), Vol. 26, pp. 391-401, CNS Drugs, C1

Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial

M Berk, O Dean, S Cotton, C Gama, F Kapczinski, B Fernandes, K Kohlmann, S Jeavons, K Hewitt, K Moss, C Allwang, I Schapkaitz, H Cobb, A Bush, S Dodd, G Malhi

(2012), Vol. 10, BMC Medicine, C1

Adjunctive antioxidants for bipolar disorder

P Magalhaes, O Dean, A Andreazza, M Berk, F Kapczinski

(2012), pp. 1-11, The Cochrane collaboration, Oxford, England, C1-1

Effects of N-acetyl cysteine on cognitive function in bipolar disorder

O Dean, A Bush, D Copolov, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2012), Vol. 66, pp. 514-517, Psychiatry and Clinical Neurosciences, C1

Qualitative methods in early-phase drug trials : data and methods from a trial of N-acetylcysteine in schizophrenia

M Berk, A Munib, O Dean, G Malhi, K Kohlmann, I Schapkaitz, S Jeavons, F Katz, M Anderson-Hunt, P Conus, B Hanna, R Otmar, F Ng, D Copolov, A Bush

(2011), Vol. 72, pp. 909-913, Journal of clinical psychiatry, [Memphis, Tenn.], C1-1

N-acetylcysteine in psychiatry: Current therapeutic evidence and potential mechanisms of action

O Dean, F Giorlando, M Berk

(2011), Vol. 36, pp. 78-86, Journal of Psychiatry and Neuroscience, C1-1

N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: Relevance to schizophrenia and bipolar disorder

O Dean, M Van Den Buuse, M Berk, D Copolov, C Mavros, A Bush

(2011), Vol. 499, pp. 149-153, Neuroscience Letters, C1-1

Role of dopamine D 3 and serotonin 5-HT 1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine- lesioned rat model of Parkinson's disease

M Gerlach, G Bartoszyk, P Riederer, O Dean, M Van Den Buuse

(2011), Vol. 118, pp. 1733-1742, Journal of Neural Transmission, C1-1

Antioxidant treatments for schizophrenia

P Magalhaes, A Andreazza, M Berk, F Kapczinski, O Dean

(2011), pp. 1-13, Cochrane database of systematic reviews, Oxford, U. K., C1-1

N-acetyl cysteine add-on treatment for bipolar II disorder: A subgroup analysis of a randomized placebo-controlled trial

P Magalh�es, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 129, pp. 317-320, Journal of Affective Disorders, C1-1

Dimensions of improvement in a clinical trial of N-acetyl cysteine for bipolar disorder

P Magalh�es, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 23, pp. 87-88, Acta Neuropsychiatrica, C1-1

Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors

M Berk, F Kapczinski, A Andreazza, O Dean, F Giorlando, M Maes, M Y�cel, C Gama, S Dodd, B Dean, P Magalh�es, P Amminger, P McGorry, G Malhi

(2011), Vol. 35, pp. 804-817, Neuroscience and Biobehavioral Reviews, C1-1

The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial

M Berk, O Dean, S Cotton, C Gama, F Kapczinski, B Fernandes, K Kohlmann, S Jeavons, K Hewitt, C Allwang, H Cobb, A Bush, I Schapkaitz, S Dodd, G Malhi

(2011), Vol. 135, pp. 389-394, Journal of Affective Disorders, C1

Who's left? Symptoms of schizophrenia that predict clinical trial dropout

J Thompson, M Berk, O Dean, K Kohlmann, S Jeavons, A Bush, D Copolov

(2011), Vol. 26, pp. 609-613, Human Psychopharmacology, C1-1

N-acetylcysteine for major depressive episodes in bipolar disorder

P Magalh�es, O Dean, A Bush, D Copolov, G Malhi, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, M Berk

(2011), Vol. 33, pp. 374-378, Revista Brasileira de Psiquiatria, C1

Effects of N-acetyl-cysteine treatment on glutathione depletion and a short-term spatial memory deficit in 2-cyclohexene-1-one-treated rats

K Choy, O Dean, M Berk, A Bush, M van den Buuse

(2010), Vol. 649, pp. 224-228, European Journal of Pharmacology, C1-1

Interaction of glutathione depletion and psychotropic drug treatment in prepulse inhibition in rats and mice

O Dean, A Bush, M Berk, D Copolov, M van den Buuse

(2010), Vol. 97, pp. 293-300, Pharmacology Biochemistry and Behavior, C1-1

Oxidative pathways as a drug target for the treatment of autism

K Villagonzalo, S Dodd, O Dean, K Gray, B Tonge, M Berk

(2010), Vol. 14, pp. 1301-1310, Expert Opinion on Therapeutic Targets, C1-1

The validity and internal structure of the Bipolar Depression Rating Scale: Data from a clinical trial of N-acetylcysteine as adjunctive therapy in bipolar disorder

M Berk, S Dodd, O Dean, K Kohlmann, L Berk, G Malhi

(2010), Vol. 22, pp. 237-242, Acta Neuropsychiatrica, C1-1

Nail-biting stuff? The effect of N-acetyl cysteine on nail-biting

M Berk, S Jeavons, O Dean, S Dodd, K Moss, C Gama, G Malhi

(2009), Vol. 14, pp. 357-360, CNS Spectrums, C1-1

Glutathione depletion in the brain disrupts short-term spatial memory in the Y-maze in rats and mice

O Dean, A Bush, M Berk, D Copolov, M van den Buuse

(2009), Vol. 198, pp. 258-262, Behavioural Brain Research, C1-1

Role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice

O Dean, M van den Buuse, A Bush, D Copolov, F Ng, S Dodd, M Berk

(2009), Vol. 16, pp. 2965-2976, Current Medicinal Chemistry, C1-1

Effects of N-acetylcysteine on substance use in bipolar disorder: A randomised placebo-controlled clinical trial

M Bernardo, S Dodd, C Gama, D Copolov, O Dean, K Kohlmann, S Jeavons, I Schapkaitz, M Anderson-Hunt, A Bush, M Berk

(2009), Vol. 21, pp. 239-245, Acta Neuropsychiatrica, C1-1

N-Acetyl Cysteine for Depressive Symptoms in Bipolar Disorder-A Double-Blind Randomized Placebo-Controlled Trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, A Bush

(2008), Vol. 64, pp. 468-475, Biological Psychiatry, C1-1

N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia-A Double-Blind, Randomized, Placebo-Controlled Trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, F Judd, F Katz, P Katz, S Ording-Jespersen, J Little, P Conus, M Cuenod, K Do, A Bush

(2008), Vol. 64, pp. 361-368, Biological Psychiatry, C1-1

Glutathione: a novel treatment target in psychiatry

M Berk, F Ng, O Dean, S Dodd, A Bush

(2008), Vol. 29, pp. 346-351, Trends in Pharmacological Sciences, C1-1

Oxidative stress in psychiatric disorders: Evidence base and therapeutic implications

F Ng, M Berk, O Dean, A Bush

(2008), Vol. 11, pp. 851-876, International Journal of Neuropsychopharmacology, C1-1

N-acetylcysteine for antioxidant therapy: Pharmacology and clinical utility

S Dodd, O Dean, D Copolov, G Malhi, M Berk

(2008), Vol. 8, pp. 1955-1962, Expert Opinion on Biological Therapy, C1-1

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

M Berk, D Copolov, O Dean, K Lu, S Jeavons, I Schapkaitz, M Anderson-Hunt, F Judd, F Katz, P Katz, S Ording-Jespersen, J Little, P Conus, M Cuenod, K Do, A Bush

(2008), Vol. 64, pp. 361-368, Biological Psychiatry, Philadelphia, Pa., C1-1

A pilot randomized, double-blind, placebo-controlled study of granisetron in the treatment of sexual dysfunction in women associated with antidepressant use

S Jespersen, M Berk, C Van Wyk, O Dean, S Dodd, C Szabo, C Maud

(2004), Vol. 19, pp. 161-164, International Clinical Psychopharmacology, C1-1